ViaBio and Langhua Pharmaceutical Strategic Integration Agreement accelerate the upgrading of the innovative pharmaceutical industry service chain.

Viabio's mission is to be the cradle of innovative biotech companies worldwide, with the world's leading structured drug discovery service platform.
's pre-clinical drug development services for global biotech and pharmaceutical customers through the Service For Cash (CFS) model, and the incubation of high-potential biotech start-ups worldwide through the Service-for-Equity (EFS) model.
Langhua Pharmaceuticals as a comprehensive pharmaceutical research and development and manufacturing company, is committed to become the customer's preferred CDMO partner, mainly engaged in small molecule API and intermediate production and CDMO business.
Langhua Pharmaceuticals was named the most growing pharmaceutical international company in 2017, with clients including a number of multinational pharmaceutical companies around the world, with the GMP certification of the National Drug Administration (NMPA), the U.S. Food and Drug Administration (FDA), the European Drug Quality Administration (EDQM), the World Health Organization, and the Pharmaceutical Supply Chain Management Board (PSCI).
through this strategic integration, Viabio will be able to have a proven and proven and reputable CDMO platform in real time, broaden the diversity and geographic coverage of its client base, expand CDMO's CDMO business to the company's existing and potential customer base through more comprehensive end-to-end services, effectively increase the revenue streams of CFS business, and empower future high-growth service needs of the incubator soragecompanies under the EFS model, expanding potential incubation portfolios.
viaBio will further strengthen and expand the drug research, development and production capacity of both parties, including but not limited to expanding their CMC capabilities and integrating their business operations with the Group's existing operations, based on the existing core strengths.
to become a preferred partner for integrated outsourcing services of multinational pharmaceutical companies and innovative biotechnology companies by providing more abundant and quality services to enhance market competitiveness.
Note: The original text has a limitation.